News
12-11-2012, 02:20 AM
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented by Peter A. Kaufman, M.D...
More... (http://www.medicalnewstoday.com/releases/253781.php)
More... (http://www.medicalnewstoday.com/releases/253781.php)